Open-house biologics rebate agreements 2026 – 29: rituximab (finished medicinal products only)

Summary

The procurement concerns rebate agreements for the active substance rituximab, covering finished medicinal products only and excluding products in a dosage form for subcutaneous injection. Agreements are intended to run from 1 December 2026 for up to 24 months and will end no later than 30 November 2028, regardless of the date of conclusion.